Updated Study Data Suggests Efruxifermin Benefits Stage 2 or 3 MASH
Over the past few years, Akero Therapeutics has experienced high highs and low lows in its efforts to advance efruxifermin, an investigational drug for people living with metabolic dysfunction-associated steatohepatitis…